不难预见,未来相关行业政策将力促连锁药店领域集中度提升,投资扮演并购者角色的连锁药店龙头企业,或将给资本带来丰厚回报。老百姓大药房近日进入证监会IPO新增审核企业中的消息令业界振奋,这不仅因为如果老百姓大药房成功上市,将成为A股市场上第一家连锁零售药店,填补行业空白。更因为冬藏了许久的连锁药店资本市场会因此破冰。 It is not difficult to foresee that the relevant industry policies in the future will push the concentration of chain pharmacies to a certain extent and invest in leading drug chain pharmacies that act as mergers and acquisitions or will bring huge returns to capital. The large pharmacy recently entered the SFC IPO review of new business news so that the industry excited, not only because if the successful listing of large pharmacies, will become the A-share market, the first chain of retail pharmacies to fill the gaps in the industry. More because winter possession of a long chain pharmacy capital markets will therefore ice.